XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, ...
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is a small clinical-stage biopharmaceutical company headquartered in Israel, operating with a lean management and scientific structure typical for early development organizations. The company’s core purpose is to identify, acquire (where applicable), and develop drug candidates aimed at addressing unmet medical needs, particularly in autoimmune ...XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is a small clinical-stage biopharmaceutical company headquartered in Israel, operating with a lean management and scientific structure typical for early development organizations. The company’s core purpose is to identify, acquire (where applicable), and develop drug candidates aimed at addressing unmet medical needs, particularly in autoimmune disorders where current treatment options can be limited by efficacy, durability, or tolerability.
Business focus and pipeline: The company’s central development program is hCDR1, an investigational compound/peptide associated with targeted therapeutic potential in autoimmune conditions. Based on the provided company description and related overview information, hCDR1 is positioned to move into Phase II trials, with specific therapeutic targets including systemic lupus erythematosus (SLE) and Sjogren’s syndrome. This indicates that XTLB is not a commercial-stage pharmaceutical vendor; instead, it is oriented around clinical proof-of-concept and therapeutic validation through human studies.
Licensing and intellectual property: A key element of XTLB’s strategy is its licensing agreement with Yeda Research and Development Company Limited. The license provides rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. For an R&D-driven company, such licensing arrangements are central to both the timeline and the economics of commercialization—because the company’s ability to advance the candidate and secure future value depends on the scope and enforceability of the licensed rights.
Products and services: XTLB’s “product” is primarily the drug development program itself—advancing a defined investigational asset through regulatory steps such as protocol design, clinical execution, data generation, and submission activities. Like many biotech firms at this stage, the company’s activities generally include trial planning, patient recruitment/management (often in partnership with specialized clinical organizations), manufacturing readiness (as required for clinical supply), and scientific/medical affairs.
Costs and BOM (typical for the business model): While the dataset does not provide a bill of materials, the cost structure for a clinical-stage biotech commonly includes personnel (small team), clinical trial operations, contract research/clinical sites, regulatory and quality systems, and drug formulation/manufacturing for clinical dosing. The supplied metrics also reflect the reality that early-stage companies often have limited or no revenue and may carry negative profitability.
Financial context: The provided overview contains indicators consistent with a pre-commercial organization—e.g., negative profitability/returns and no dividend history. Market capitalization data in the source snapshot is comparatively small, aligning with the company’s early development posture. Free cash flow metrics and operating cash flow ratios can be negative for development-focused firms due to ongoing research spend without commercialization revenues.
Key people and governance: The supplied information lists Noam Band as Chief Executive Officer. The overview also references prior leadership and board involvement by other biotech-experienced individuals, reflecting the importance of executive and board guidance in clinical strategy, financing, and partnering.
Overall, XTLB’s near-term “wish list” is aligned with advancing hCDR1 through clinical milestones (notably Phase II), generating credible efficacy/safety data for its targeted autoimmune indications, and strengthening the path toward eventual commercialization rights and partnerships. For investors and stakeholders, the primary value drivers are typically clinical progress, the quality/interpretation of trial results, and the company’s ability to finance development until key inflection points.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
-100.0%
+78.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-7.0M
-578.6%
+53.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
-114.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
+40.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
+74.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-1.0M
+38.7%
—
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-105.9%
-4271.0%
-4271.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.40x
-34.9%
-34.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
